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Electroacupuncture for tapering off long-
term benzodiazepine use: study protocol of
randomized controlled trial
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Connie Lai-Wah Chan6, Lai-Ming Ho7, Yee-Man Yu1 and Li-Xing Lao3
Abstract
Background: Conventional approaches for benzodiazepine tapering have their limitations. Anecdotal studies have
shown that acupuncture is a potential treatment for facilitating successful benzodiazepine tapering. As of today,
there was no randomized controlled trial examining its efficacy and safety. The purpose of the study is to evaluate
the efficacy of using electroacupuncture as an adjunct treatment to gradual tapering of benzodiazepine doses in
complete benzodiazepine cessation in long-term benzodiazepine users.
Methods/Design: The study protocol of a randomized, assessor- and subject-blinded, controlled trial is presented.
One hundred and forty-four patients with histories of using benzodiazepines in ≥50% of days for more than 3 months
will be randomly assigned in a 1:1 ratio to receive either electroacupuncture or placebo electroacupuncture combined
with gradual benzodiazepine tapering schedule. Both experimental and placebo treatments will be delivered twice per
week for 4 weeks. Major assessments will be conducted at baseline, week 6 and week 16 post-randomization. Primary
outcome is the cessation rate of benzodiazepine use. Secondary outcomes include the percentage change in the
doses of benzodiazepine usage and the severity of withdrawal symptoms experienced based on the Benzodiazepine
Withdrawal Symptom Questionnaire, insomnia as measured by the Insomnia Severity Index, and anxiety and
depressive symptoms as evaluated by the Hospital Anxiety and Depression Scale. Adverse events will also
be measured at each study visit.
Discussion: Results of this study will provide high quality evidence of the efficacy and safety of electroacupuncture as
an adjunct treatment for benzodiazepine tapering in long-term users.
Trial registration: ClinicalTrials.gov NCT02475538.
Keywords: Benzodiazepine discontinuation, Withdrawal, Acupuncture, Sham, RCT
Background
Benzodiazepines are commonly prescribed for short-term
relief of anxiety and insomnia symptoms. Despite the
initial intention, some patients continue taking the drugs
and become long-term benzodiazepine users. Cross-
sectional studies indicated that 58–84% of benzodiazepine
users reported taking the drugs for longer than 6 months
[1, 2]. In a population-based survey in Switzerland, nearly
one-tenth of 520,000 participants reported at least one
benzodiazepine use in the last 6 months and among the
benzodiazepine users, 56% were taking the drug for more
than 90 days [3]. The potential harms due to long-term
benzodiazepine use, including abuse, dependence, over-
dose, cognitive impairment, household, work and road
accidents, and falls, often outweigh its benefits [4–6]. Par-
ticularly in the elderly, benzodiazepine use, both short and
long term, has been associated with increased risk of
daytime drowsiness, accidents and falls, hip fractures and
mortality [5]. Studies have shown that a high proportion
of long-term benzodiazepine users have attempted to stop
or reduce taking the drug; however, many of them have
failed due to benzodiazepine withdrawal symptoms [7].
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Benzodiazepine withdrawal symptoms, such as insomnia,
anxiety, hand tremor, sweating, muscle pain and irritability
are common [8]. A study showed that 43% of 180 partici-
pants who were taking diazepam for longer than 8 months
experienced withdrawal symptoms on cessation of use [9].
Another study indicated that 35% of 109 patients with
panic disorder reported withdrawal symptoms when an
8-week course of alprazolam was stopped [10]. Gradual
reduction or in combination with substitutive pharmaco-
therapy or psychological intervention are conventional
approaches for tapering benzodiazepines [11, 12]. Accord-
ing to a meta-analysis including both adults and older
adults, the average cessation rate was 42% for gradual
benzodiazepine reduction in routine care. There were no
significant benefits for gradual reduction in combination
with substitutive pharmacotherapy [11]; however, combin-
ing gradual reduction with psychological intervention was
more effective than gradual reduction alone (OR = 1.82,
95% CI = 1.25–2.67) [11]. Psychological intervention may
have helped patients to attain motivation and confidence
or have reduced their levels of anxiety and insomnia dur-
ing benzodiazepine withdrawal [13]. While the existing
conventional tapering approaches need further trials to
confirm their effectiveness, exploring complementary and
alternative therapies is therefore suggested.
Complementary and alternative medicine is a group of
diverse medical and healthcare practices that are not
presently considered to be a part of conventional medicine.
A recent systematic review showed that the 12-month
prevalence of complementary and alternative medicine use
ranged between 9.8 and 76% [14]. Complementary and
alternative medicine therapies can be an alternative treat-
ment to patients than substitutive pharmacotherapy or psy-
chological intervention as treatments of benzodiazepine
tapering. Acupuncture is one of the commonly-used com-
plementary and alternative medicine therapies. According
to the traditional Chinese medicine theory, fine needles are
inserted at special points on the body, called acupoints, to
produce therapeutic effects [15]. Electroacupuncture is a
special technique of acupuncture. Instead of manual stimu-
lation, electricity is used to stimulate acupoints via inserted
acupuncture needles. Previous systematic reviews have
shown that acupuncture is efficacious in alleviating anxiety
symptoms in subjects with anxiety [16] and in improving
sleep quality in subjects with a chief complaint of insomnia
[17, 18]. Anecdotal reports have been performed to exam-
ine whether acupuncture can augment gradual benzodi-
azepine tapering in enhancing benzodiazepine cessation
rate [19–21]. Ruan et al. showed that the use of hypnotics
was reduced from 7.6 times per week to 3.2 times per week
after a 2-month course of electroacupuncture in 32 subjects
with insomnia and hypnotic dependence [19]. In another
study, the cessation rate of hypnotics was over 90%
after 10 sessions of manual acupuncture [20]. Another
study showed that all subjects could stop using their
benzodiazepines for anxiety following a 2-month manual
acupuncture treatment and 80% of the subjects attained a
Hamilton Anxiety Rating Scale score below 14 [21]. How-
ever, these studies adopted a retrospective recall on the
use of benzodiazepine, which is vulnerable to recall bias
and the reliability is limited. Besides these uncontrolled
studies, to the best of our knowledge, there has been no
randomized placebo-controlled study on the efficacy and
safety of electroacupuncture as an adjunct treatment of
gradual benzodiazepine withdrawal in enhancing benzodi-
azepine cessation rate. We therefore planned to conduct a
randomized controlled trial to examine the short- (2-week
posttreatment) and medium-term (12-week posttreat-
ment) effects of electroacupuncture in a group of long-
term benzodiazepine users in Hong Kong.
Methods
Objective
This study aims to examine the efficacy and safety of
electroacupuncture as an adjunct treatment to gradual
benzodiazepine withdrawal in enhancing benzodiazepine
cessation rate in long-term (at least 3 months) benzodi-
azepine users. The short-term and medium-term effects of
electroacupuncture were defined as within 4 weeks and 4–
12 weeks after completion of the electroacupuncture treat-
ment course. We hypothesize that subjects receiving
electroacupuncture will have a higher benzodiazepine
cessation rate than those receiving non-invasive placebo
acupuncture at 2-week posttreatment (short-term, week 6
post-randomization) and 12-week posttreatment (medium-
term, week 16 post-randomization).
Trial design
This study is a randomized, parallel-group, assessor- and
subject-blinded controlled trial with a 1:1 ratio of group
allocation to receive electroacupuncture plus gradual ta-
pering of benzodiazepines or placebo electroacupunc-
ture plus gradual tapering. Design and reporting of the
study will follow the CONSORT [22] and STRICTA [23]
recommendations.
Ethical approval
The study will be conducted in compliance with local
law, Declaration of Helsinki (1989), institutional policies and
the Good Clinical Practice (ICH-GCP) guidelines to protect
subjects’ right and safety. Ethics approval has been obtained
from the Institutional Review Board of the University of
Hong Kong/Hospital Authority Hong Kong West Cluster
(UW 14–554), Research Ethics Committee of Hospital
Authority Kowloon Central/Kowloon East Cluster (KC/
KE-15-0178/FR-3) and Human Subjects Ethics Sub-
committee of the Hong Kong Polytechnic University
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(HSEARS20160509002). The trial has been registered at
ClinicalTrials.gov (NCT02475538).
Participants
A total of 144 subjects who are long-term benzodiazepine
users will be recruited from psychiatric outpatient clinics of
three regional hospitals in Hong Kong and an integrative
health clinic. We have planned an 18-month recruitment
period starting from July 2015.
Inclusion criteria
Subjects will be included if they are: (1) 18 years or
above in age including elderly patients; (2) having at
least one of the psychiatric diagnoses that are listed in
Table 1; (3) taking one or more benzodiazepines, coded
as N05BA, N05CD, N05CF, and M03BX07 according to
the World Health Organization Anatomical Therapeutic
Chemical classification system [24], on more than 50%
of days for at least 3 months and during a prospective
2-week period prior to baseline; and (4) willing to taper
benzodiazepines as per protocol.
Exclusion criteria
We will exclude participants who have: (1) any increase
by 50% or higher in the dosage of antidepressants or
anxiolytics in the past 1 year; (2) scored ≥8 in either the
depression or anxiety subscale of the Hospital Anxiety
and Depression Scale (HADS) [25]; (3) any concurrent
psychiatric disorders on the exclusion list (Table 1); (4)
any unstable psychiatric conditions or serious physical
illnesses which are judged by the investigator to render
unsuitable or unsafe to join the study; (5) valvular heart
defects or bleeding disorders, taking anticoagulant drugs,
or are fitted with any implanted electrical device such as
pacemaker, defibrillator, or brain stimulation; (6) acu-
puncture during the previous 6 months prior to baseline;
(7) pregnancy, breastfeeding or childbearing potential
but not using adequate contraception; (8) infection or
abscess close to the site of selected acupoints and in the
investigator’s opinion inclusion is unsafe; and (9) signifi-
cant suicidal risk as rated by the Hamilton Depression
Rating Scale (HDRS) [26] item on suicide (a score ≥ 3).
Trial procedure (Fig. 1)
Potential subjects will be invited to attend a face-to-face
interview for written consent, psychiatric history, and
history of benzodiazepine use. We will request partici-
pants to complete a daily record of benzodiazepine use
in the 2 weeks prior to baseline. Those who use benzodi-
azepines for more than 50% of days are eligible for
randomization. Participants will be randomly assigned to
receive electroacupuncture plus gradual tapering or
placebo electroacupuncture plus gradual tapering in a
1:1 ratio. Block randomization will be administrated by
an independent administrator using a computer-generated
list of random sequence. Group allocation will be kept in
sequentially-numbered opaque-sealed envelopes and will
be opened by acupuncturists after all baseline assessments
have been completed by the research assistant who is
blind to treatment allocation.
Intervention
Electroacupuncture combined with gradual tapering.
Subjects will receive electroacupuncture twice per
week for 4 consecutive weeks. The frequency and duration
Table 1 Lists of included and excluded psychiatric disorders
according to the ICD-10 system
Included
F32.0 Mild depressive episode;
F32.1 Moderate depressive episode;
F32.8 Other depressive episodes;
F32.9 Depressive episode, unspecified;
F33.0 Recurrent depressive disorder, current episode mild;
F33.4 Recurrent depressive disorder, currently in remission;
F33.1 Recurrent depressive disorder, current episode moderate;
F33.8 Other recurrent depressive disorders;
F33.9 Recurrent depressive disorder, unspecified;
F41.0 Panic disorder;
F41.1 Generalized anxiety disorder;
F41.2 Mixed anxiety and depressive disorder;
F43.2 Adjustment disorders;
F51.0 Nonorganic insomnia
Excluded
F31.0 Bipolar affective disorder;
F42.0 Obsessive-compulsive disorder;
F43.1 Post-traumatic stress disorder;
F20.0 Schizophrenia;
F21–29 other Schizotypal and delusional disorders;
F55.0 Abuse of non-dependence-producing substances;
F10–12, F14–19 Abuse of other psychoactive substances Fig. 1 Flowchart of study procedures
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are based on previous systematic reviews [16–18] and
experts’ opinions. Subjects will be needled at bilateral
EX-HN1 (Sishencong), EX-HN22 (Anmian), GB8 (Shuaigu),
ST8 (Touwei), EX-HN5 (Taiyang), GB15 (Toulinqi), PC6
(Neiguan), HT7 (Shenmen), SP6 (Sanyinjiao), LV3
(Taichong), unilateral EX-HN3 (Yintang), GV24 (Shenting),
and GV20 (Baihui). The location and indication are sum-
marized in Table 2. The total number of needles used in
each session will be fixed to 23. The acupoints have been
used for treating insomnia and mood disorders [16, 27–29]
and modified for the purpose of benzodiazepine tapering
according to our expert team.
After sterilizing the skin around the acupoints with
75% alcohol, sterilized disposable needles (Blister Needle,
Dong Bang, Korean, 0.25x30mm) will be inserted. “De qi”
(a radiating feeling of numbness or distension considered
to be indicative of effective needling as reported by the
participant) will be achieved if possible. It is an indication
of “effective needling” in terms of TCM theory. Four pairs
of needles (left and right EX-HN1; GV20-EX-HN3; left
GB8- ST8; and right GB8- ST8) will be connected to an
electric-stimulator (AWQ 104 L, Hong Kong) for continu-
ous stimulation at constant current and a frequency of
4 Hz. In clinical practice, acupuncturists usually select 1–
4 pairs of acupoints to deliver electric stimulation. These
four pairs of acupoints were chosen to deliver electric-
stimulation because they are the main acupoints that are
supposed to have anxiolytic and sedative effects according
to the TCM theory. The amplitude of electrical stimula-
tion will be adjusted to a comfortable level. The needles
will be left for 30 min and then removed which resembles
the duration used in clinical practice.
All the included subjects will be advised to taper their
benzodiazepines over 4 weeks according to a protocol as
suggested by Rickels et al. [30]. The baseline benzodi-
azepine dosage in diazepam equivalent will be calculated
based on the average daily consumption in the 2 weeks
prior to baseline [31]. Subjects will be asked to reduce
their daily dose by 25% in the first and second week. For
the remaining 50%, we will advise reduction by 12.5%
for 3–4 days each time (Fig. 2). Where tablets do not
allow precise dose reduction, tablets will be either cut in
half or spaced over alternative days as required. After
the second, fourth, sixth, and eighth electroacupuncture
sessions, the subjects will be asked to complete a Benzo-
diazepine Withdrawal Symptom Questionnaire [32] to
assess their withdrawal symptoms, then a trained research
assistant who is blinded to the treatment allocation will use
about 10–15 min to evaluate subjects’ benzodiazepine with-
drawal symptoms and other adverse events, discuss the
problems encountered due to benzodiazepine tapering,
count the surplus of benzodiazepines due to dose reduc-
tion, set the withdrawal schedule for the following weeks,
and provide support and encouragement to follow the
withdrawal schedule. If subjects find it too difficult to cope,
feel unable to meet the reduction goal, or have at least one
item in the Benzodiazepine Withdrawal Symptom Ques-
tionnaire [32] rated as severe, we will suggest keeping the
dosage unchanged or slowing down the tapering, e.g., the
25% per week tapering in the first 2 weeks can be reduced
to 12.5% per week.
Placebo electroacupuncture combined with gradual
tapering
The sterilization procedure will be the same as in elec-
troacupuncture group. Placebo needles, designed by
Streitberger [33], have a blunt tip that cannot penetrate
the skin. The handles of placebo needles will slide over
the needle when they are pressed, giving an appearance
of penetrating the skin. The placebo needles will be
placed 1 in. beside the acupoints in order to avoid acu-
pressure effect. The needles are held by surgical tape or
hair pin to imitate the procedure of electroacupuncture.
The needles are connected to an electric-stimulator with
zero frequency and amplitude. The number, duration and
frequency of treatment session will be the same as in the
electroacupuncture group.
Electroacupuncture will be performed according to
a standard operating procedure (SOP) manual which
is developed to standardize the treatment procedure
and dialogue between acupuncturists and subjects
(Additional file 1).
Fidelity of the intervention
The acupuncturists are registered Chinese medicine prac-
titioners in Hong Kong with a Bachelor degree in Chinese
Medicine and at least 5 years’ experience in providing nee-
dle acupuncture. Their first 10 electroacupuncture treat-
ments will be assessed and guided by the PI (WY) using a
standardized checklist to ensure fidelity of the interven-
tion. The PI will also randomly visit to check the acupunc-
turists’ adherence to the research protocol.
Outcome measures (Table 3)
Primary outcome
Primary outcome is the proportion of participants who
successfully discontinue benzodiazepines at 2-week post-
treatment (week 6) and 12-week posttreatment (week
16). Previous randomized controlled trials of benzodi-
azepine tapering [10] have used cessation rate as the
main outcome measure. The primary end-point is 12-
week posttreatment (Fig. 2).
Secondary outcomes
Secondary measures include percentage benzodiazepine
dose reduction, Benzodiazepine Withdrawal Symptom
Questionnaire (BWSD), Insomnia Severity Index (ISI),
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and HADS. A daily dose of benzodiazepine in diazepam
equivalent and percentage reduction as compared to
baseline will be derived from a 14-day record form. Pre-
vious studies have suggested that prospective usage diary
is more accurate than retrospective recall of consump-
tion [34, 35]. The subject will be asked to bring back
their un-used medications at each visit for cross-
checking with the usage record.
Benzodiazepine withdrawal symptoms will be assessed
by the 20-item self-administrated BWSQ [32]. The items
include main symptoms experienced during withdrawal
from benzodiazepine dependent patients including dizzi-
ness, pains in muscle, muscle twitching, and so on [32].
Withdrawal symptoms are rated as “absent”, “moderate”
or “severe” (0, 1, or 2), yielding a total score ranging be-
tween 0 and 40. The original English version has been
translated into Chinese for use in this study. The back-
translated version has been compared with the original
version to ensure it appropriately reflects the original
version. Insomnia, one of the most common benzodi-
azepine withdrawal symptoms, will be further evaluated
by the ISI [36]. The ISI is a 7-item 5-point self-rating
Likert scale to indicate subjects’ perceived severity of in-
somnia symptoms. The total score ranges from 0 to 28.
The Chinese version of ISI has been demonstrated to have
adequate validity and reliability [37]. The HADS [25], a
validated and widely-used self-reported questionnaire, will
be adopted to measure the severity of depressive and anx-
iety symptoms. It consists of 14 items; seven of them are
on depression and seven on anxiety, which generates the
anxiety and depression subscales. Somatic symptoms are
not included in the HADS. The validated Chinese version
of HADS will be used in the present study [38].
Treatment expectancy
The Credibility of Treatment Rating Scale (CTRS), a
4-item scale, will be used for assessing subjects’ confi-
dence and expectation towards treatment [39]. The
Chinese version CTRS has been adopted in previous
studies [27, 29]. Higher scores indicate greater confi-
dence and expectation towards treatment.
Fig. 2 Benzodiazepine gradual tapering schedule
Table 3 Summary of outcome measures and assessment schedule
Measure Baseline Intervention 2-week
posttreatment
12-week
posttreatment2nd 4th 6th 8th
BZ cessation ratea ✓ ✓ ✓
BZ dose reduction, % ✓ ✓ ✓ ✓ ✓ ✓ ✓
BWSQ ✓ ✓ ✓ ✓ ✓ ✓ ✓
ISI ✓ ✓ ✓ ✓
HADS ✓ ✓ ✓ ✓
SDS ✓
CTRS ✓ ✓ ✓
AE monitoring ✓ ✓ ✓ ✓ ✓ ✓
BZ Benzodiazepine, BWSQ Benzodiazepine Withdrawal Symptom Questionnaire, ISI Insomnia Severity Index, HADS Hospital Anxiety and Depression Scale, SDS
Substance Dependence Scale, CTRS Credibility of Treatment Rating Scale, AE adverse events
aPrimary outcome
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Assessment for substance dependence
The Substance Dependence Scale (SDS) measures the
severity of dependency towards a particular substance in
the last 12 months [40]. The SDS contains five items
and the Chinese version has been shown to be reliable
and valid [41]. The term “particular substance” in the
SDS will be revised to “benzodiazepine” in this study.
Safety concern
Subjects will be provided with sufficient information
regarding the potential adverse events of benzodiazep-
ine withdrawal. Benzodiazepine withdrawal symptoms,
and electroacupuncture-related adverse events will be
assessed at each study visit. Benzodiazepine withdrawal
symptoms will be assessed by the BWSQ. A standardized
electroacupuncture-related adverse event form [42, 43],
consisting of eight items on adverse events around the
needle sites, 13 items on systemic adverse events, and
three items on serious adverse events, will be used. Sever-
ity of each adverse event will be rated as “absent”, “mild”,
“moderate” or “severe” and the causality of adverse event
will be reported using a 5-point Likert scale, ranging from
“unrelated” to “certain”. In addition, worsening of pre-
existing medical and psychiatric conditions is counted as
adverse events. Subjects with heart rate over 100 beats per
minute, systolic blood pressure higher than 140 mmHg,
diastolic blood pressure higher than 90 mmHg, and any
suicidal risk based on the HDRS suicidality item will be
evaluated by the Principal Investigator before continuing
in the study. Those with moderate suicidal risk will be ex-
cluded from the study and referred to their case doctors
as early as possible.
Blinding assessment
As all outcome measures are self-reported, assessments
are deemed to be blinded. Success of participant blinding
will be measured at the last electroacupuncture session.
Subjects will be asked a standard question: “When you
volunteered for the trial, you were informed that you
would receive traditional acupuncture, or acupuncture-
like placebo treatment. Which acupuncture do you think
you received?” The standard question is adapted from the
paper by Park et al. [44].
Sample size calculation
Sample size calculation is based on benzodiazepine
cessation rate, the primary outcome. No previous studies
have been conducted on the efficacy of electroacupuncture
and placebo electroacupuncture for tapering benzodiaze-
pines; hence the effect size for sample size calculation is
estimated according to previous randomized controlled
trials using psychological intervention. A median cessa-
tion rate of 74% (range = 13–85%) was reported in a
previous systematic review on benzodiazepine tapering
using psychological intervention [11]. We estimate that
electroacupuncture will produce a cessation rate similar
to that of psychological intervention (75%) and the cessa-
tion rate in placebo control group is about 50%; hence. a
25% difference in cessation rate between groups is assumed
[27]. A power of 80% has been regarded as a reasonable
protection against Type II error [45]. Based on a 25%
between-group difference and a power of 80%, the minimal
number of subjects that are required to avoid a Type I error
of 0.05 is 108 (54 per group). The final sample size is 144
(72 per group) after allowing a 25% attrition rate at 12-
week posttreatment.
Statistical analysis
Data will be double-entered and checked for consistency.
Data analysis will be performed with an identification code
of group A and group B according to a pre-specified stat-
istical analysis plan. The coding of group allocation will be
revealed after the completion of data analysis or in case of
reports of serious adverse events associated with electroa-
cupuncture or benzodiazepine withdrawal. Between-group
difference will be assessed by two-sample t-test or chi-
square test at baseline, week 4 (end of treatment), week 6
(2-week posttreatment), and week 16 (12-week posttreat-
ment). The absolute risk reduction and number of
subjects that are needed to be treated to obtain one
benzodiazepine withdrawal will be estimated at week 16.
Attempts will be made for minimizing missing data
among subjects who do not return for assessment or have
withdrawn from study by mail and phone reminders. Both
per protocol and intention-to-treat analyses will be per-
formed. Multiple imputation technique will be used to
handle missing values, assuming data are missing at ran-
dom (MAR). Ten sets of imputed values will be generated
to adjust for variability due to imputation, and so ten
completed data sets will be created. These completed data
sets will be analyzed separately with standard statistical
methods, and the results are combined into a single
multiple-imputation result [46]. Sensitivity analysis will be
conducted to examine the effect of departures from the
assumption of MAR on clinical outcomes. The missing
data due to dropout cases may be associated with those
who rebound in insomnia or anxiety levels, or those who
fail to decrease consumption of benzodiazepine. Pattern
mixture models with various possible values of the in-
formative missing parameters will be employed to conduct
the sensitivity analysis [47]. For dichotomous outcomes,
the informative missing parameter specifies the odds ratio
between the outcome and missingness indicator. For con-
tinuous outcomes, it specifies the mean difference be-
tween the unobserved outcome and observed outcome.
By varying the informative missing parameter, it is possible
to examine the magnitude of departures from MAR
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assumption on different outcomes. Stata rctmiss will be
used to do the sensitivity analysis [48].
Trial status
Subject recruitment has been started in late July 2015
and is expected to complete in March 2017. Results of
the study will be available by the end of 2017. The
current study does not include any interim analyses.
Discussion
Benzodiazepine is one of the most frequently prescribed
drugs. Although benzodiazepines play an important role
in the treatment of anxiety disorders, insomnia, and
physical illnesses such as epilepsy, their use has been
questioned due to public concerns about adverse effects
and liability to lead to physical dependence and abuse.
Despite legislative measures to control the prescription
of benzodiazepines [49], long-term benzodiazepine use
remains common. Gradual reduction of benzodiazepines
with or without substitutive pharmacotherapy or psycho-
logical intervention have their limitations, the present study
will explore using electroacupuncture as an adjunct for
benzodiazepine tapering. In this trial, we aimed to examine
the specific effects of electroacupuncture such as nee-
dle insertion, deqi sensation, and electric-stimulation in
tapering off benzodiazepine use. Therefore, we used a
non-invasive sham as a control. Our next step is to per-
form a pragmatic trial on the effectiveness of electroa-
cupuncture compared to other standard interventions
(e.g. psychological or pharmacological intervention) for
tapering benzodiazepines.
To the best our knowledge, we are the first group to
perform a randomized placebo-controlled trial using a
well-documented screening process and validated scales
to examine the efficacy and safety of electroacupuncture
for benzodiazepine tapering. Results of this study will
enrich our understanding on the use of electroacupunc-
ture for benzodiazepine cessation.
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